INTRODUCTION
T HE CURRENT STANDARD of Care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated-interferon (PEG-IFN) with ribavirin (RBV), 1 may activate underlying autoimmune conditions such as thyroiditis 2 or systemic lupus erythematosus. 3 Particularly, interferon (IFN) has been known to induce or exacerbate autoimmune hepatitis (AIH) [4] [5] [6] [7] [8] [9] [10] and primary biliary cirrhosis (PBC) 11, 12 in hepatitis C virus (HCV) patients. We describe a severe, acute-onset antimitochondrial antibody (AMA)-M2 positive AIH appearing during the last weeks of SoC in a woman with chronic hepatitis C and no previous history of autoimmunity, and resolving on protracted steroids. Table 1 ) alanine aminotransferase (ALT) was twice the upper limit of normal (u.l.n.) while g-glutamiltransferase (GGT), alkalyne phosphatase (AP) and bilirubin were normal. Non-organ specific autoantibodies (NOSAs, tested by indirect immunofluorescence for antinuclear antibody (ANA), AMA, SMA and by immunoblotting for AMA type M2, liver kidney/microsome type 1 [LKM-1], LC1, soluble liver antigen/liver pancreas [SLA/LP]) were negative. At biopsy a pattern of mild chronic hepatitis (grade 2/3, stage 1/4 according to Scheuer's classification) and no sign of PBC or AIH were evidenced (Fig. 1a) . Immunohistochemistry for cytokeratin 7 (CK7 antibody, clone OV-TL12/30, Dako; Dako A/S, Glostrup, Denmark) highlighted the presence of normal portal bile ducts, without reactive bile duct proliferation (Fig. 1b) . The intrahepatic immunoglobulin (Ig) IgG/ IgM plasma cells assessment (polyclonal anti-IgG and anti-IgM; Novocastra, Newcastle, United Kingdom) showed a low number of portal plasma cells with an IgM plasma cell number < 4/portal tract (Fig. 1c ).
CASE REPORT
An intended course of 48 weeks of SoC (PEG-IFN a-2b 1.5 mg/kg per week; RBV 1000 mg/day) was started in September 2005. HCV-RNA was undetectable (<50 IU) at week 4 and week 12, and all liver tests were normal at week 12. At week 42 a slight rise of AST (2 x u.l.n.) and ALT (1.5 x u.l.n.) was noted. GGT, AP and bilirubin were normal, and HCV-RNA still negative.
Therapy was stopped at week 48 in August 2006. At the time of stopping, AST and ALT were nine and 11 times the u.l.n., GGT seven times the u.l.n., AP 2.5 times the u.l.n., total bilirubin 6.1 mg/dL and HCV RNA negative. The patient had no itching or any physical complaints. A detailed medical history ruled out a potential involvement of hepatotoxic drugs, herbal remedies, dietary supplements or alcohol consumption. Abdominal US showed normal gallbladder and bile ducts. Ten days after discontinuing SoC (see Table 2 ), AST and ALT were 14 and 13 times the u.l.n., GGT seven times the u.l.n., AP three times the u.l.n., and total bilirubin 6.5 mg/dL, with no reduction of serum albumin or INR. Hepatitis B surface antigen (HBsAg), IgM Anti-hepatitis A virus (HAV), IgM anti-viral capsid antigen (VCA), IgM anticytomegalovirus (CMV) were all negative, and HCV RNA once more undetectable. AMA type M2 had become positive (+++ by immunoblotting), while all other NOSAs were negative. IgM and IgG serum levels were 170 and 2150. The human leukocyte antigen (HLA) profile was: DRB1-11, DRB3, DQB1-03. 7 A liver biopsy (August 2006) showed severe periportal lymphocytic piecemeal necrosis with abundant plasma cells in the portal and periportal infiltrate and pseudorosettes formed by hepatocytes, suggesting AIH. Severe hepatocellular damage with ballooning degeneration, apoptotic bodies, centro-zonal necrosis and small bile duct proliferation, as highlighted by CK7 antibody, were present, all of them characteristic of an acute -onset ( Fig. 2a-d ). On the other hand, despite the AMA-M2 positivity, no features of PBC such as small bile duct damage, portal peri-ductal granulomas and peri-portal orcein-positive granules, or markers of chronic chola- 
DISCUSSION
I NDUCTION OR EXACERBATION of AIH and PBC is a known complication of SoC for chronic hepatitis C. In our case, a definite diagnosis was not initially easy to reach. The scoring system formulated in 1999 by the International Autoimmune Hepatitis Group (IAIHG) is extremely useful for the diagnosis of AIH. 13 Regarding hepatitis viral markers as negative (and this was probably correct, since HCV RNA was persistently undetectable), the score defined the autoimmune disease in our patient as "probable" AIH. Nevertheless, its applicability remains unclear in a PBC/AIH Overlap Syndrome context, since a score of "definite" AIH can be very rarely observed in patients with characteristic overlap syndrome, whereas nearly 20% of PBC subjects could be classified with "probable" AIH overlap. [14] [15] [16] Moreover, the simplified diagnostic score recently proposed by the IAIHG has not been validated in patients with suspected PBC-AIH Overlap Syndrome. 17 Using the simple diagnostic criteria proposed by Chazouilleres et al. 18 and recently highlighted by the European Association for the Study of the Liver (EASL), 19 our patient could also be classified in the context of a PBC/AIH Overlap Syndrome, as we suspected before the liver biopsy just regarding the laboratory findings and the autoantibodies profile. Nevertheless, liver biopsy showed only the histological features of an acute-onset AIH (severe periportal lymphocytic piecemeal necrosis with many plasma cells in the portal and periportal infiltrate, presence of hepatocytic rosettes, severe hepatocellular damage with ballooning degeneration, apoptotic bodies and centrozonal necrosis) without alterations typical of PBC (bile duct damage, portal peri-ductal granulomas and chronic cholatostasis, as evidenced by peri-portal orcein-positive granules).
Furthermore, the presence of numerous IgM plasma cells in the portal tracts has been reported in PBC. 20 We recently reported the increase of portal IgM plasma cells (13 IgM plasma cells/portal tract was the cut-off value) with an IgG/IgM plasma cells ratio <1 as specific of both PBC and "autoimmune cholangitis" patients (AIC), 21 a firmly accepted variant of PBC (AMA-negative PBC). 22 Ursodeoxycholic acid (UDCA) treatment should be preferred for these patients, independently of the presence or absence of AMA. On the other hand, all patients with AIH, PBC/AIH or AIC/AIH overlap syndromes showed an IgG/IgM ratio >1 and less than 13 IgM plasma cells/ portal tract, so a therapeutic approach with steroids or steroids and UDCA should be preferred for these cases. 21 In our patient, even if suggested by the AMA type M2 positivity and by the elevation of cholestatic liver enzymes, a diagnosis of PBC was unlikely for two reasons. First, AMA negativity by conventional indirect immunofluorescence at the initial diagnosis and, second, the absence of chronic non-suppurative destructive cholangitis (CNSDC) or granulomas by histopathological examinations. Moreover, the very low IgM plasma cells number (less than four cells/portal tract) with an IgG/ IgM ratio >1 made a PBC or AIC diagnosis increasingly unlikely. Thus, our case is devoid of any histological and immunohistochemical features of PBC and the rapid elevation of cholestasis markers could be more easily explained by considering the acute setting of the disease.
On the other hand, AMA type M2 positivity is not an exclusion criterion for "simple" AIH: a recent study 23 has reported some cases of AMA positive AIH with no clinical or histologic evidence of PBC despite the continued detection of AMAs over a follow-up of up to 27 years. Other authors observed that clinical and histological features of AIH were not influenced by the AMA status. 24 AMA-M2 positive AIH has been reported in the literature and, to our knowledge, this is the first case in which an acute cholestatic onset and the role of IFN as trigger has been shown. In this setting, the relevance of the characterization of the immunoglobulin isotype of portal plasma cells for a more appropriate diagnosis of autoimmune liver diseases can be emphasized. 
